A sponsor shall submit an IND to FDA if the sponsor intends to conduct a clinical investigation with an investigational new drug that is subject to 312.2(a) Submit an IND if any exempt criteria are not met If you are uncertain if an IND is required, please contact the Research Institute.
{}